Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01005251 · ClinicalTrials.gov registry record · Phase 2
Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 661
- Enrollment target
NCT01005251 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 661 participants.
The verdict
NCT01005251, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 661 participants
- Enrollment target
Study Summary
This study is being carried out to see whether AZD3355 is an effective treatment as an add-on to PPI therapy in patients with Gastroesophageal Reflux Disease (GERD) with a partial response to PPI and to compare this with Proton Pump Inhibitor (PPI) treatment alone. Another goal of the study is to examine which of the investigated doses of AZD3355 is optimal for treatment of these patients. This study will also measure levels of drug in the blood and see how well it is tolerated.
Interventions
- DRUG Placebo
- DRUG lesogaberan (AZD3355)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 661 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01005251
The ClinicalTrials.gov registry entry for NCT01005251 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 661 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01005251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01005251 about?
NCT01005251 is a clinical study titled "Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI". This study is being carried out to see whether AZD3355 is an effective treatment as an add-on to PPI therapy in patients with Gastroesophageal Reflux Disease (GERD) with a partial response to PPI and to compare this with Proton Pump Inhibitor (PPI) treatment alone. Another goal of the study is to ex...
What is the current status of trial NCT01005251?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 661 participants. The study started on 2009-10. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01005251?
The interventions under investigation include: Placebo (DRUG), lesogaberan (AZD3355) (DRUG).
Who is sponsoring clinical trial NCT01005251?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.